financetom
Business
financetom
/
Business
/
National Bank On Air Canada and Transat After May CPI Data Showed Airfares Up YoY
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National Bank On Air Canada and Transat After May CPI Data Showed Airfares Up YoY
Jun 25, 2024 7:42 AM

10:28 AM EDT, 06/25/2024 (MT Newswires) -- National Bank said Tuesday that airfares in Canada rose 4.5% year over year in May, and 15.6% versus 2019, according to Canadian CPI data for May.

Among highlights, National noted the year-over-year increase in May follows a flat print in April and a 2.9% year-over-year increase in March, which was the first year-over-year increase since March 2023. Fares were up 2.3% sequentially after declining 5.7% sequentially in April.

The May increase versus 2019, National also noted, was "roughly in line" with the April increase versus 2019 of 15.7% but lower than the March increase of 24%.

"Airfares in Canada have strengthened the last three months following an 11-month stretch of y/y declines (on difficult comparables) and remain well ahead of pre-pandemic levels," the National Bank analysts said.

On Air Canada ( ACDVF ) , National Bank has an "Outperform" rating and a price target of $30. On Transat A.T ( TRZBF )., National Bank has an "Underperform" rating and a price target of $2.25.

During its Q2 results earlier in June, Transat said that it is experiencing some yield softness on trans-Atlantic routes this summer with its summer load factor currently tracking about 2 points lower year over year and yields down 8%.

"Air Canada ( ACDVF ) will also likely see some yield deterioration this summer on its Atlantic routes due to difficult comparisons and higher industry capacity. We note, however, that our own fare surveys for Air Canada ( ACDVF ) suggest that domestic pricing is generally higher y/y on the key routes that we track," the analysts added.

On last look on Tuesday in Canada, Air Canada ( ACDVF ) was down 1.2% while Transat A.T ( TRZBF ). dropped 1.8%.

Price: 16.90, Change: -0.11, Percent Change: -0.65

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dick's Sporting Goods Poised to Report 'Strong' Q4 Results, Wedbush Says
Dick's Sporting Goods Poised to Report 'Strong' Q4 Results, Wedbush Says
Mar 6, 2025
10:38 AM EST, 03/06/2025 (MT Newswires) -- Dick's Sporting Goods (DKS) is poised to report strong Q4 results on March 11, with material upside to consensus estimates, Wedbush Securities said in an earnings preview Thursday. Wedbush said it forecasts earnings per share of $3.64 for the company, up from the brokerage's prior expectation of $3.35 and higher than the consensus...
Kroger Fourth-Quarter Earnings Beat Estimates; Issues Weak 2025 Bottom-Line Outlook
Kroger Fourth-Quarter Earnings Beat Estimates; Issues Weak 2025 Bottom-Line Outlook
Mar 6, 2025
10:37 AM EST, 03/06/2025 (MT Newswires) -- Kroger's ( KR ) fiscal fourth-quarter earnings came in ahead of market estimates but revenue missed forecasts, while the supermarket chain issued a full-year bottom-line outlook below Wall Street's expectations. The company anticipates adjusted earnings to be in a range of $4.60 to $4.80 per share for fiscal 2025, compared with the consensus...
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer
Mar 6, 2025
10:41 AM EST, 03/06/2025 (MT Newswires) -- Conduit Pharmaceuticals ( CDT ) said Thursday that a Nasdaq hearing panel granted it an extension to meet listing requirements, with plans to transfer its shares to the Nasdaq Capital Market. The company said it must submit an application for the transfer by March 12 and meet all Nasdaq listing standards by March...
Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US
Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US
Mar 6, 2025
10:37 AM EST, 03/06/2025 (MT Newswires) -- Scienture ( SCNX ) said Thursday its Scienture LLC unit signed an agreement with Summit Biosciences for the exclusive rights to commercially launch Rezenopy, a 10mg naloxone HCl nasal spray for opioid overdose treatment in the US. Financial details weren't disclosed. Under the terms of the agreement, Kindeva Drug Delivery, the parent company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved